These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15701886)

  • 21. The use of oestrogens and progestin and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589-93.
    Kauppila A
    Pharmacol Res; 1995 Dec; 32(6):327. PubMed ID: 8736481
    [No Abstract]   [Full Text] [Related]  

  • 22. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
    Colditz GA
    J Natl Cancer Inst; 1998 Jun; 90(11):814-23. PubMed ID: 9625169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing concepts: Menopausal hormone therapy and breast cancer.
    Chlebowski RT; Anderson GL
    J Natl Cancer Inst; 2012 Apr; 104(7):517-27. PubMed ID: 22427684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause.
    Davey DA
    Womens Health (Lond); 2012 Mar; 8(2):169-89. PubMed ID: 22375720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestrogens and progestins and breast cancer risk in post-menopausal women.
    La Vecchia C
    Pharmacol Res; 1995 Dec; 32(6):323-4. PubMed ID: 8736479
    [No Abstract]   [Full Text] [Related]  

  • 28. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormones and breast cancer: evidence and implications for consideration of risks and benefits of hormone replacement therapy.
    Colditz GA
    J Womens Health; 1999 Apr; 8(3):347-57. PubMed ID: 10326989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
    Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
    PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer risk in women receiving estrogen-progestin replacement therapy.
    Persson I
    Maturitas; 1996 May; 23 Suppl():S37-45. PubMed ID: 8865138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.
    Jick SS; Hagberg KW; Kaye JA; Jick H
    Obstet Gynecol; 2009 Jan; 113(1):74-80. PubMed ID: 19104362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study.
    Shapiro S; deVilliers TJ; Pines A; Sturdee DW; Archer DF; Baber RJ; Panay N; Farmer RD; Stevenson JC; Mueck AO; Burger HG; Gompel A
    J Natl Cancer Inst; 2014 Feb; 106(2):djt372. PubMed ID: 24363446
    [No Abstract]   [Full Text] [Related]  

  • 34. Different menopausal hormone regimens and risk of breast cancer.
    Brusselaers N; Tamimi RM; Konings P; Rosner B; Adami HO; Lagergren J
    Ann Oncol; 2018 Aug; 29(8):1771-1776. PubMed ID: 29917061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports.
    Speroff L
    Climacteric; 2000 Mar; 3(1):3-12. PubMed ID: 11910607
    [No Abstract]   [Full Text] [Related]  

  • 36. Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.
    Chlebowski RT; Anderson GL
    Steroids; 2014 Nov; 90():53-9. PubMed ID: 24910928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
    J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.
    Doherty JA; Cushing-Haugen KL; Saltzman BS; Voigt LF; Hill DA; Beresford SA; Chen C; Weiss NS
    Am J Obstet Gynecol; 2007 Aug; 197(2):139.e1-7. PubMed ID: 17689625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women.
    Newcomb PA; Longnecker MP; Storer BE; Mittendorf R; Baron J; Clapp RW; Bogdan G; Willett WC
    Am J Epidemiol; 1995 Oct; 142(8):788-95. PubMed ID: 7572954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.